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The GATA family of transcription factors plays
fundamental roles in cell-fate specification.
However, it is unclear if these genes are neces-
sary for the maintenance of cellular differentia-
tion after development. We identified GATA-3
as the most highly enriched transcription factor
in the mammary epithelium of pubertal mice.
GATA-3 was found in the luminal cells of mam-
mary ducts and the body cells of terminal end
buds (TEBs). Upon conditional deletion of
GATA-3, mice exhibited severe defects inmam-
mary development due to failure in TEB forma-
tion during puberty. After acute GATA-3 loss,
adult mice exhibited undifferentiated luminal
cell expansion with basement-membrane de-
tachment, which led to caspase-mediated cell
death in the long term. Further,FOXA1was iden-
tified as a downstream target of GATA-3 in the
mammary gland. This suggests that GATA-3 ac-
tively maintains luminal epithelial differentiation
in the adult mammary gland, which raises im-
portant implications for the pathogenesis of
breast cancer.
INTRODUCTION
A fundamental aspect of development is the specification
andmaintenance of the differentiated cell state. The spec-
ification of cell fate ismediated in part by the establishment
of hierarchical networks of transcription factors and the
cis-regulatory elements that control their expression
(Davidson et al., 2002; Swiers et al., 2006). Transcription
factors are organized into structurally similar multigene
families, such as the GATA and FOX families. These genes
play essential roles in activating target genes of specific
cell fates and also in repressing target genes of alternate
cell fates (Singh et al., 2005). Key mechanisms that under-Celllie target gene activation and repression are chromatin
remodeling and DNA methylation, which modulate the
accessibility of transcriptional activation complexes to
target gene loci. Though the roles of transcription factors
in specifying cell fate have been established, it is unclear
how cells maintain the differentiated state in the adult or-
ganism. That is, it is unclear whether the genetic regulatory
networks that establish cell specification are necessary to
maintain cell fate after development has completed.
The GATA family of transcription factors is a group of six
highly conserved transcription factors that play funda-
mental roles in cell-fate specification (Patient andMcGhee,
2002). GATA factors bind the DNA sequence (A/T)GATA
(A/G) via a DNA binding domain containing one or two
zinc-finger domains. One of the best-characterized func-
tions of GATA factors is the essential role of GATA-1 in
erythropoeisis. GATA-1 is essential for the specification of
erythroid cells from myelo-erythroid progenitors, whereas
the Ets family transcription factor PU.1 is essential for the
specification of myeloid cells (Cantor and Orkin, 2001).
GATA-1 and PU.1 exhibit transcriptional crossantagon-
ism, thereby blocking the ability of a specified cell to adopt
the alternate cell fate. Accordingly, the loss of GATA-1
causes a conversion of erythropoiesis to myelopoiesis,
leading to a deficiency of erythroid cells and an expansion
of myeloid cells (Galloway et al., 2005). A similar phenom-
enon has been observed for GATA-3 in T helper(Th)2 cell-
fate specification. GATA-3 and the T box family transcrip-
tion factor T-bet play essential roles in the specification of
naive T helper cells into Th2 and Th1 effector cells, respec-
tively (Grogan and Locksley, 2002). GATA-3 and T-bet also
exhibit transcriptional crossantagonism to repress the
alternate cell fate. Interestingly, it was recently suggested
that GATA-3 expression must be sustained to maintain
the differentiated Th2 cell type (Pai et al., 2004).
Themammary gland is a ductal epithelial organ that, like
the Th1/Th2 system, contains two mature epithelial cell
types: the luminal epithelial cells, which line the ductal lu-
men and secretemilk proteins, and themyoepithelial cells,
which line the basal surface of the luminal cells. These dif-
ferentiated cell types arise from a multipotent progenitor
population that has been recently characterized (Shackle-
tonet al., 2006). Prior to theonset of puberty, themammary127, 1041–1055, December 1, 2006 ª2006 Elsevier Inc. 1041
gland is a rudimentary organ consisting of a primitive
network of ductal epithelium. Shortly after the onset of
puberty, specialized structures known as TEBs develop
at the invading epithelial tips of the mammary epithelium.
TEBscontain anouter layer of capcells,which arebelieved
to be myoepithelial progenitors, and a multilayered inner
core of body cells, which may be luminal cell progenitors
(Smalley and Ashworth, 2003). The TEBs proliferate, bifur-
cate, and invade into the fatty stroma of the mammary
gland in a process known as branching morphogenesis.
The process continues until 10–12 weeks of age, at which
point the TEBs have invaded the entire length of the fat pad
and then regress, having given rise to a mature ductal tree
(Sternlicht et al., 2006).
Little is known about the differentiation of the luminal
cells, which are the principal cells implicated in breast can-
cer. Efforts to understand luminal cell differentiation have
focused on the estrogen receptor (ERa), which is found in
asubsetof luminal cells that exhibit lowproliferation (Cheng
et al., 2004). ERa is found in only half ofmature luminal cells
and is found in fibroblasts and other stromal cells. Mice
lacking ERa exhibit defects in mammary development,
including an inability to form TEBs and defects in ductal
invasion, though differentiation markers such as milk pro-
teins are still expressed in its absence (Mallepell et al.,
2006). In this report, we carry out a genome-wide screen
and identifyGATA-3 as themost highly enriched transcrip-
tion factor in the mammary ductal epithelium of pubertal
mice. We show that GATA-3 is localized to the body cells
of TEBs and to themature luminal cells of mammary ducts.
Usinga loss-of-functionapproach,weshow thatGATA-3 is
necessary in vivo for mammary development and for the
maintenance of the differentiated luminal epithelium.
RESULTS
GATA-3 Expression in the Mammary Gland
We devised a microarray strategy to identify novel regula-
tors ofmammary development. b-actin-GFP reportermice
were used to visualize the mammary epithelium in vivo
(Hadjantonakis et al., 1998). TEBs, mature ducts, and epi-
thelium-free stromal microenvironments were surgically
microdissected from 5-week-old b-actin-GFP mice, and
RNA was immediately isolated for analysis (Figure 1A).
The RNA expression profiles of the TEB and mature-duct
microenvironments were compared to the epithelium-
free stroma by using long-oligonucleotide spotted micro-
arrays with 19,500 features. An analysis of the most highly
enriched genes in the mammary epithelium revealed that
members of the keratin family (keratins 8 and 19) were
the most highly enriched genes in the TEB microenviron-
ment, whereas members of the casein family (casein k
and casein a) were the most highly enriched genes in the
mature-duct microenvironment (Table 1). In this analysis,
we identified GATA-3 as the most highly enriched tran-
scription factor in both the TEB (13.9-fold change) andma-
ture-duct (10.6-fold change) microenvironments. A full1042 Cell 127, 1041–1055, December 1, 2006 ª2006 Elsevier Ianalysis of the microarray data can be found elsewhere
(Kouros-Mehr and Werb, 2006).
We further investigated the localization of the GATA-3
protein by immunofluorescence. GATA-3 was found in all
luminal cells of mature ducts, both within pubertal (5-
week-old) and adult (12-week-old) virgin mice (Figures
1C and 1D). Costaining with a-smooth muscle actin
(SMA) revealed that SMA-positive myoepithelial cells
were GATA-3 negative, suggesting that GATA-3 was re-
stricted to the luminal cells of the mammary gland
(Figure 1D). GATA-3 was also expressed in the body cells
of TEBs; however, the intensity of GATA-3 staining was
lower in the distal end of the TEB (i.e., nearest to the in-
vading front) compared to the proximal end (Figure 1B).
GATA-3 was not found in the cap cells of the TEB
(Figure 1B, arrowhead).
GATA-3 Is Necessary for Mammary Development
We used a loss-of-function strategy to study the role of
GATA-3 in the mammary gland. GATA-3 null mice display
embryonic lethality between days 11 and 12 postcoitum,
so we were unable to use these mice to study mammary
development (Pandolfi et al., 1995). Instead, we used the
Cre/loxP recombination system to generate mice that
were conditionally deficient inGATA-3.Mice with a floxed
GATA-3 locus were obtained, as described elsewhere (Pai
et al., 2003). In the floxed construct, exons 4 and 5 of the
nativeGATA-3 locus were replaced by a cassette contain-
ing exons 4, 5, and 6, flanked by loxP sites. The loxP sites
were further flanked by a phosphoglycerokinase (PGK)
promoter and an enhanced green fluorescent protein
(GFP) cassette, such that Cre-mediated recombination
led to the placement of the GFP immediately downstream
of the PGK promoter. We thus used GFP as a marker of
Cre-mediated recombination to assess the efficiency of
GATA-3 deletion.
We first crossed the floxedGATA-3mousewith the con-
stitutively activeMMTV-Cre line,whereCreexpressionhas
been reported in themammarygland, skin, salivary glands,
and other sites (Wagner et al., 2001). Homozygous floxed
mice carrying the MMTV-Cre transgene (MMTV-Cre;
GATA-3flox/flox) were born in normal Mendelian ratios com-
pared to their littermates (data not shown). This suggested
that the conditional deletion approach rescued the embry-
onic lethality that had been observed inGATA-3 null mice.
Whereas heterozygous floxed mice expressing MMTV-
Cre (MMTV-Cre; GATA-3flox/+) appeared in all respects
normal compared to non-Cre littermate controls (Non-Tg;
GATA-3flox/x), MMTV-Cre; GATA-3flox/flox exhibited severe
defects in their skin and mammary glands beginning at
puberty. MMTV-Cre; GATA-3flox/flox mice began to lose
hair shortly after puberty, and by adulthood, these mice
displayed total alopecia. The mice also exhibited other
major skin defects, including epidermal hyperplasia, der-
mal fibrosis, and hyperkeratosis (data not shown).
The development of the mammary gland was severely
disrupted in MMTV-Cre; GATA-3flox/flox mice. Prior to pu-
berty at day 19 postpartum, MMTV-Cre; GATA-3flox/floxnc.
Figure 1. Expression of GATA-3 in the
Mammary Gland
(A) Schematic representation of the microarray
profiling strategy. Top, number 4 mammary
gland of a 5-week-old b-actin-GFP mouse.
TEBs, epithelium-free distal stroma (Stroma),
and mature ductal epithelium (Mature duct)
regions were microdissected for microarray
profiling. Modified from Kouros-Mehr and
Werb (2006).
(B and C) Immunofluorescence for GATA-3
(red) and DAPI (blue) in TEBs (B) and mature
ducts (C) of 5-week-old mammary glands.
Arrowheads denote cap cell layer of distal TEB.
(D) Costaining for GATA-3 (green), a-smooth
muscle actin (SMA, red), and DAPI (blue) in
12-week-old wild-type mammary glands.
Arrowheads denote myoepithelial cells.
Scale bars correspond to 1 mm in (A) and 25
mm in (B)–(D).mice contained a rudimentary mammary gland that ap-
peared to be similar to littermate controls by whole-mount
inspection (Figures 2A and 2B). However, with the onset ofCepuberty, the mammary glands of MMTV-Cre; GATA-3flox/
flox mice failed to develop TEBs (Figures 2C and 2D). As
a result, by 5 weeks postpartum, the ductal epitheliumll 127, 1041–1055, December 1, 2006 ª2006 Elsevier Inc. 1043
Table 1. The Most Highly Enriched Genes in the Mammary Epithelium
TEBs Mature Ducts
Gene Name Genbank Ma Gene Name Genbank Mb
keratin complex 2, gene 8 NM_031170 6.2 casein kappa NM_007786 6.2
keratin complex 1, gene 19 NM_008471 5.4 casein alpha NM_007784 5.7
DNA segment, ERATO 251 BC002307 5.4 DNA segment, ERATO 251 BC002307 5.1
Extracellular protease inhib NM_007969 5.3 keratin complex 1, gene 18 NM_010664 5.0
keratin complex 1, gene 18 NM_010664 5.2 keratin complex 2, gene 8 NM_031170 5.0
claudin 3 NM_009902 4.5 casein gamma NM_007785 4.9
tumor-associated calcium
signal transducer 1
NM_008532 4.4 tumor-associated calcium
signal transducer 1
NM_008532 4.5
casein kappa NM_007786 4.4 lamin B1 NM_009972 4.3
serine protease inhibitor, Kt2 NM_011464 4.1 mucin 15 BC020027 4.2
CD24a antigen NM_009846 4.0 CD24a antigen NM_009846 4.1
aldolase 3, C isoform NM_009657 4.0 aldolase 3, C isoform NM_009657 3.9
small proline-rich protein 2A NM_011468 3.9 Extracellular protease inhib NM_007969 3.9
GATA-3 NM_008091 3.8 keratin complex 1, gene 19 NM_008471 3.7
small proline-rich protein 1A NM_009264 3.7 serine protease inhibitor, Kt2 NM_011464 3.5
amphiregulin NM_009704 3.6 claudin 3 NM_009902 3.5
retinol binding protein 1 NM_011254 3.5 lactotransferrin NM_008522 3.4
RIKEN 1600029D21 gene NM_029639 3.5 GATA-3 NM_008091 3.4
FXYD ion transport reg 3 NM_008557 3.4 secreted phosphoprotein 1 NM_009263 3.3
keratin complex 2, gene 7 NM_033073 3.3 RIKEN 1600029D21 gene NM_029639 3.3
cysteine-rich secretory LCCL
domain containing 2
NM_030209 3.3 lactalbumin, alpha NM_010679 3.3
aM = log2(Cy5/Cy3) ratio where Cy5 labeled TEB RNA and Cy3 labeled stroma RNA (n = 6).
bM = log2(Cy5/Cy3) ratio where Cy5 labeled Duct RNA and Cy3 labeled stroma RNA (n = 6).failed to invade into the fatty stroma and remained in
a compact and highly defective state (Figures 2E, 2F,
and 2I). At 8 weeks postpartum, a few sporadic TEBs
emerged in MMTV-Cre; GATA-3flox/flox mammary glands,
but these TEBs were incapable of filling the mammary
stroma by 30 weeks postpartum, suggesting that GATA-
3 played an essential role for normal TEB function (Figures
2G–2I). Moreover, the 8-week-old null outgrowths dis-
played gross structural defects, including irregular luminal
diameters and deficiencies in side branching (Figure 2H).
Histologic analysis of the MMTV-Cre; GATA-3flox/flox
outgrowths further demonstrated an essential role for
GATA-3 in mammary development. Hematoxylin and eo-
sin (H&E) staining showed profound defects in the luminal
epithelium of 8-week-old MMTV-Cre; GATA-3flox/flox out-
growths (Figure 3A). Whereas MMTV-Cre; GATA-3flox/+
ductal epithelium contained a single layer of luminal cells,
theMMTV-Cre;GATA-3flox/floxductal epitheliumcontained
regions that lacked luminal cells and regions that con-
tained amultilayered luminal epithelium (Figure 3B, arrow-
heads). Interestingly, immunostaining revealed that these1044 Cell 127, 1041–1055, December 1, 2006 ª2006 Elsevier Idefective outgrowths remained GATA-3 positive despite
having undergone recombination (GFP+) (Figure 3B). The
multilayered epithelium in the null outgrowths contained
a basally located population of GATA-3/GFP double-pos-
itive luminal cells andadistinct population ofGFP-positive,
GATA-3-negative cells in the ductal lumen (Figure 3B, yel-
low arrowhead). A similar histologic profile was observed
in 19-day-old MMTV-Cre;GATA-3flox/flox outgrowths (data
not shown).
To determine the mechanism for the expression of
GATA-3 in the 8-week-old MMTV-Cre; GATA-3flox/flox
outgrowths, we purified genomic DNA from the recom-
bined (GFP+) cells of MMTV-Cre; GATA-3flox/+ and
MMTV-Cre; GATA-3flox/flox mammary glands. PCR analy-
sis using primers specific to wild-type, floxed, and deleted
GATA-3 loci revealed that the null outgrowths contained
a nondeleted GATA-3 allele despite being GFP+ (Fig-
ure 3C). Thus, there was a selective pressure to retain a
functionalGATA-3allele in the survivingoutgrowths,which
further suggested that GATA-3 is essential for mammary
development.nc.
Figure 2. Constitutive Loss of GATA-3 in
the Mammary Gland Causes Defect in
Ductal Invasion
(A–H) Carmine-stained, number 4 mammary
glands from 19-day-old to 8-week-old MMTV-
Cre; GATA-3flox/flox (n = 20) and MMTV-Cre;
GATA-3flox/+ (n = 18) mice. Shown are repre-
sentative mammary glands for each time point
(n = 4–6 mammary glands per time point). fl/fl,
GATA-3flox/flox and fl/+, GATA-3flox/+ in (A)–(I).
Scale bar corresponds to 3 mm.
(I) Ductal invasion in MMTV-Cre;
GATA-3flox/flox, MMTV-Cre; GATA-3flox/+, and
nontransgenic (Non-Tg); GATA-3flox/+ mam-
mary glands, represented as distance from
proximal end of primary duct to distal TEB.
Data are represented as mean ± SEM, n =
4–6 mammary glands per condition, *p < 0.01
(Student’s t test).Cell 127, 1041–1055, December 1, 2006 ª2006 Elsevier Inc. 1045
Figure 3. GATA-3 Is Essential for Mam-
mary Development
(A) H&E staining of 8-week-old MMTV-Cre;
GATA-3flox/flox and MMTV-Cre; GATA-3flox/+
mammary glands. fl/fl, GATA-3flox/flox and fl/+,
GATA-3flox/+in (A) and (B).
(B) Immunofluorescence for GATA-3 (red), GFP
(green), and DAPI (blue) in 8-week-old
MMTV-Cre; GATA-3flox/flox and MMTV-Cre;
GATA-3flox/+ mammary glands. White arrow-
head denotes missing luminal epithelium and
yellow arrowhead denotes GATA-3 null cells
in ductal lumen.
Scale bars represent 25 mm in (A) and (B).
(C) PCR analysis of wild-type (WT) GATA-3,
floxed (Fl) GATA-3, and deleted (Del) GATA-3
loci in 30-week-old MMTV-Cre; GATA-3flox/
flox, MMTV-Cre; GATA-3flox/+, and Non-Tg;
GATA-3flox/+ mammary glands. Genomic DNA
from the GFP+ (recombined) cell population of
30-week-old MMTV-Cre; GATA-3flox/flox and
MMTV-Cre; GATA-3flox/+ was purified for PCR
analysis. Whole-mammary epithelial DNA was
used for Non-Tg; GATA-3flox/+ analysis.1046 Cell 127, 1041–1055, December 1, 2006 ª2006 Elsevier Inc.
GATA-3 Is Necessary for the Maintenance of the
Luminal Epithelium in the Adult Mammary Gland
To further analyze the molecular function of GATA-3 in the
mammary gland, we crossed the floxed GATA-3 mouse
with the mammary-specific, doxycycline-inducible Cre
line WAP-rtTA-Cre. Cre expression in the latter is both
highly specific to themammary gland and tightly regulated
by doxycycline administration (Utomo et al., 1999). This
enabled us to study the role of GATA-3 in the mammary
gland while minimizing possible secondary effects from
GATA-3 deletion in other organs. Furthermore, this ap-
proach enabled us to delete GATA-3 in the adult mam-
mary gland after development had taken place.
We administered doxycycline to 12-week-old WAP-
rtTA-Cre; GATA-3flox/flox and WAP-rtTA-Cre; GATA-3flox/+
miceandanalyzedGFPexpression todetermine the timing
and efficiency of recombination. GFP was not detected in
the absence of doxycycline administration, indicating that
there was no leakiness of Cre expression. Although GFP
was not detectable after a 3 day course of doxycycline,
by5daysof doxycycline, high levels ofGFPwereobserved
throughout the ductal epithelium of both WAP-rtTA-Cre;
GATA-3flox/flox andWAP-rtTA-Cre;GATA-3flox/+mammary
glands (Figure 4A). GFP was induced in a large fraction of
luminal cells but was absent in myoepithelial and stromal
cells, suggesting that WAP-rtTA-Cre was highly specific
to the luminal epithelium (Figure 4C). Interestingly, the
WAP-rtTA-Cre; GATA-3flox/flox mammary glands showed
greatly reduced GFP expression after a 14 day course of
doxycycline, whereas the WAP-rtTA-Cre; GATA-3flox/+
glands maintained a high level of GFP expression (Fig-
ure 4A). Both the relative intensity and the distribution of
GFP along the ductal epitheliumwere reduced (Figure 4A),
suggesting that these cells had been lost.
On histologic examination, the 5 and 14 day doxycy-
cline-treated WAP-rtTA-Cre; GATA-3flox/flox mammary
glands showed severe cellular defects in the luminal epi-
thelium. After 5 days of doxycycline treatment, WAP-
rtTA-Cre; GATA-3flox/flox mammary glands developed a
disorganized multilayered epithelium (Figure 4B). There
appeared to be a substantial increase in cell number and
heterogeneity of nuclear size and orientation. Detachment
of single cells into the ductal lumenwas observed, but only
sporadically (see below). After 14 days of doxycycline
treatment, WAP-rtTA-Cre; GATA-3flox/flox mammary
glands showed additional defects in the luminal epithe-
lium, including cell detachment into the ductal lumen, dis-
ruption of the ductal architecture, and widespread cell
death (Figure 4B). In some areas, individual luminal cells
detached from the basementmembrane, whereas in other
areas, large portions of ductal epithelium detached (Fig-
ure 4B). No phenotype was observed in 5 or 14 day doxy-
cycline-treated WAP-rtTA-Cre; GATA-3flox/+ mammary
glands (Figure 4B).
Immunostaining of WAP-rtTA-Cre;GATA-3flox/floxmam-
mary glands verified that GATA-3 was lost after doxy-
cycline administration. In 5 day doxycycline-treated
WAP-rtTA-Cre; GATA-3flox/floxmammary glands, we iden-Celltified two populations of luminal cells: a GATA-3-positive
population lining the basement membrane and a GATA-
3-negative population that had detached from the base-
ment membrane (Figure 4C, white arrow). Both popula-
tions expressed similar levels of GFP, suggesting that
only the subset of recombined luminal cells that lost the
GATA-3 protein had detached from the basement mem-
brane at this time point. In 14 day doxycycline-treated
WAP-rtTA-Cre; GATA-3flox/flox mammary glands, we de-
tected a single population of GATA-3-positive, GFP-nega-
tive cells.Wedid not detectGFP-positive cells in histologic
analysis, suggesting that recombined cells had undergone
negative selection by this time point (Figure 4C). Taken
together, these data suggest that GATA-3 is necessary in
adult mammary glands tomaintain the integrity of the lumi-
nal epithelium.
Acute Loss of GATA-3 Leads to the Expansion
of Undifferentiated Luminal Cells
To characterize the immediate consequences of GATA-3
deletion in the adult mammary gland, we further immuno-
stained the 5 day doxycycline-treated WAP-rtTA-Cre;
GATA-3flox/floxmammary glands with structural and differ-
entiation markers. Coimmunostaining with the luminal
marker keratin 18 and the myoepithelial marker keratin
14 revealed that themultilayered epithelium in 5 day doxy-
cycline-treated WAP-rtTA-Cre; GATA-3flox/flox mammary
glands was exclusively keratin 18 positive, suggesting
that they retained luminal character and had not trans-
differentiated into myoepithelial cells (Figure 5A).
Despite being a luminal cell population, the 5 day doxy-
cycline-treated WAP-rtTA-Cre; GATA-3flox/flox epithelium
expressed significantly reduced levels of luminal differen-
tiation markers (Figures 5B–5D). There was a substantial
reduction of b-casein immunostaining in the null mammary
glands compared to littermate controls (Figure 5B). There
was also a reduction of E-cadherin and an absence of
ERa in the null cells that exhibited detachment from the
basement membrane (Figures 5C and 5D). To verify these
findings, we compared the RNA expression profiles of 5
day doxycycline-treated WAP-rtTA-Cre; GATA-3flox/flox
and WAP-rtTA-Cre; GATA-3flox/+ whole mammary glands
by microarray (Figure 5E). The data confirmed that there
was a relative increase in the expression levels of the lumi-
nal keratins 18, 19, and 8 and a decrease in various luminal
differentiation markers (including members of the casein,
cadherin, and estrogen receptor families) in the null
mammary glands compared to heterozygous controls.
These data suggested that the acute loss ofGATA-3 led
to an expansion of a luminal cell population that lacked
markers of differentiation. To confirm that this phenome-
non indeed represented cellular proliferation, we analyzed
BrdU and PCNA staining in the 5 day doxycycline-treated
mammary glands. WAP-rtTA-Cre; GATA-3flox/flox mam-
mary glands showed a significant increase of PCNA and
BrdU-positive luminal cells compared to WAP-rtTA-Cre;
GATA-3flox/+ controls, suggesting that the acute loss of
GATA-3 led to cell-cycle progression (Figures 5F and 5G).127, 1041–1055, December 1, 2006 ª2006 Elsevier Inc. 1047
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Long-Term Loss of GATA-3 Leads to Luminal-Cell
Death and Lactational Insufficiency
We determined the long-term effects of GATA-3 loss by
further characterizing the 14 day doxycycline-treated
WAP-rtTA-Cre; GATA-3flox/flox mammary glands. In
contrast to the 5 day doxycycline treatment, the 14 day
doxycycline treatment led to a relative reduction in the
number of keratin 18-positive cells in WAP-rtTA-Cre;
GATA-3flox/flox mammary glands compared to controls
(Figures 6A–6C). There was also a reduction of E-cadherin
and ERa-positive cells after 14 days of doxycycline (Fig-
ures 6B and 6C). To determine if the reduction in cell num-
ber was due to cell death, we immunostained with the ap-
optosismarkerM30, which recognizes a caspase-cleaved
epitope of keratin 18. We observed widespread M30-pos-
itive luminal cells in 14 day, but not 5 day, doxycycline-
treated WAP-rtTA-Cre; GATA-3flox/flox mammary glands
(Figures 6D and 6E). This suggested that cell death was
not a primary event after GATA-3 loss but was rather
a long-term consequence of GATA-3 loss.
The lactational competence of doxycycline-treated
WAP-rtTA-Cre; GATA-3flox/flox mice was assessed to de-
termine the functional consequence of GATA-3 loss.
WAP-rtTA-Cre; GATA-3flox/flox mice that had received
a 14 day course of doxycycline were bred and sacrificed
at day 10 postpartum. The mammary glands of WAP-
rtTA-Cre;GATA-3flox/floxmothers exhibited severe defects
in lactation as a functional consequence of GATA-3 loss,
including a reduction in the number and size of milk-
producing alveolar units (Figures 6F and 6G). As a conse-
quence of the lactational defect, the pups of null mothers
displayed a significant reduction in weight at day 10 post-
partum (Figure 6H). Doxycycline-treated WAP-rtTA-Cre;
GATA-3flox/+ mothers showed normal lactation and ex-
hibited a heterogeneous pattern of GFP expression, indi-
cating mosaicism of recombination in the WAP-rtTA-Cre
line (Figure 6F). In contrast, the ductal structures in doxy-
cycline-treated WAP-rtTA-Cre; GATA-3flox/flox mothers
wereGFP negative, which suggested there was a negative
selection for recombined cells in the WAP-rtTA-Cre;
GATA-3flox/flox mammary glands (Figure 6F).
GATA-3 Binds to the FOXA1 Promoter
in the Mammary Gland
To identify potential downstream effectors of GATA-3
signaling, we performed bioinformatic analysis of our mam-
marymicroarray data.We identified 22 transcription factors
that were highly enriched in TEBs and mature ducts of the
mammary gland, a pattern that mirrorsGATA-3 expressionCel(Figure S1A in the Supplemental Data available with this ar-
ticle online). These genes included FOXA1, FOXP4,MSX2,
TRPS1, ELF5, EHF, RUNX1, as well as several members
of the Id, Irx,Sox, and TCFAP-2 transcription factor families.
We then analyzed four independent microarray datasets to
identifywhether anyof thesegeneswereconsistently corre-
lated with GATA-3 expression in breast cancer samples.
The transcription factor FOXA1 emerged as one of the
best predictors of GATA-3 expression in these datasets.
Of24,000 genes, FOXA1 emerged as themost highly cor-
related genewithGATA-3 in two of four datasets, and it was
the second and sixth most highly correlated gene in the
other twodatasets (Bonferroni-adjustedp<0.0001 in all da-
tasets, FigureS1B). The strongpositive correlation between
GATA-3 and FOXA1 suggested a potential interaction be-
tween these transcription factors.
To explore the possible relationship between GATA-3
and FOXA1, we analyzed the 50 kb promoter sequences
of mouse and human FOXA1 and identified three con-
served GATA binding sites lying 0.8, 1.7, and 3.6 kb up-
streamof the first exon (rVista 2.0).We performed chroma-
tin immunoprecipitation (ChIP) of primary mammary
epithelial cultures with a GATA-3 antibody and then PCR
amplified the regions containing theseGATA binding sites.
The GATA binding site lying 0.8 kb upstream of the FOXA1
first exon coimmunoprecipitated with the GATA-3 anti-
body, suggesting that GATA-3 binds to the FOXA1 pro-
moter in this region (Figure 6I).
DISCUSSION
Cellular Differentiation Is Actively Maintained
in the Adult Mammary Gland
We show here for the first time that GATA-3 is a critical
regulator of luminal cell differentiation in the mammary
gland. This finding adds to the growing body of evidence
that GATA factors are important mediators of cell-fate de-
cisions in developmental systems. Examples include the
essential roles of GATA-1 in erythrocyte differentiation,
GATA-3 in T cell and Th2 cell differentiation, GATA-3 in
sympathetic neuron differentiation, GATA-4 in gastric ep-
ithelial differentiation, and GATA-6 in distal lung epithelial
differentiation (Jacobsen et al., 2002; Tsarovina et al.,
2004; Yang et al., 2002). Though the role of GATA factors
in specifying cell fate has been established, our data sug-
gest that GATA factors maintain cellular differentiation
after development has taken place. We have found that
GATA-3 actively maintains luminal epithelial differentiation
in the adult mammary gland.Figure 4. Disruption of Epithelial Architecture in Adult Mammary Glands after Induction of GATA-3 Recombination
(A)GFPmammarywholemounts from12-week-oldWAP-rtTA-Cre;GATA-3flox/+andWAP-rtTA-Cre;GATA-3flox/floxmice treated for 3 days (n=5 flox/+,
n=4flox/flox), 5days (n=4flox/+, n=5flox/flox), and14days (n=4flox/+,n=4flox/flox)withdoxycycline (dox).Cre,WAP-rtTA-Cre;fl/fl,GATA-3flox/flox;
and fl/+, GATA-3flox/+ in (A)–(C).
(B andC) H&E staining (B) and immunofluorescence (C) for GATA-3 (red), GFP (green), andDAPI (blue) in 12-week-oldWAP-rtTA-Cre;GATA-3flox/+ and
WAP-rtTA-Cre;GATA-3flox/floxmice treated for 5 days and 14 days with doxycycline. Arrowheads in (C) denote GFP-positive/GATA-3-negative cells in
ductal lumen.
Scale bars correspond to 3 mm in (A) and 25 mm in (B) and (C).l 127, 1041–1055, December 1, 2006 ª2006 Elsevier Inc. 1049
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The maintenance of differentiation is likely governed by
GATA-3 operating in a hierarchical network of transcrip-
tional activators and repressors, as has been observed in
other developmental systems (Davidson et al., 2002;
Swiers et al., 2006). We have identified FOXA1 as a puta-
tive member of the GATA-3 genetic regulatory network.
Expression of GATA-3 and FOXA1 is strongly correlated
in mammary and breast cancer microarray datasets, and
FOXA1 contains a functional GATA-3 binding site. More-
over, the overexpression ofGATA-3was shown to upregu-
late FOXA1 expression, suggesting that GATA-3 activates
gene expression (Usary et al., 2004). Interestingly, FOXA1
is essential for estrogen signaling in mammary cells and is
required for the direct interaction of ER to chromatin sites
(Carroll et al., 2005; Laganiere et al., 2005). It is possible
that FOXA1 mediates crosstalk between GATA-3 and ER
signaling in the mammary gland. Because GATA-3 is not
an estrogen-responsive gene (Hoch et al., 1999), we hy-
pothesize that GATA-3 acts upstream of ER to regulate lu-
minal gene expression. This hypothesis explains why
acute GATA-3 loss leads to ER loss and also explains the
similarity in phenotypes between GATA-3 and ERa null
mammary glands (Mallepell et al., 2006). Further work
will be necessary to define the interactions between
GATA-3, FOXA1, and ER and to further define the GATA-
3 genetic regulatory network in the mammary gland.
Our data suggest that, in addition to maintaining the
luminal cell fate in adulthood, GATA-3 plays a role in the
specification of the luminal cell fate during development.
We showed that GATA-3 is necessary for the formation
of TEBs, which perform the essential developmental func-
tions in this organ.Within the TEBs, GATA-3 is restricted to
the body cells, which include putative luminal progenitor
cells (Smalley and Ashworth, 2003). The inability of TEBs
to develop in the absence of GATA-3 may be due to a fail-
ure in luminal progenitor specification. However, as direct
evidence establishing the body cell as the bona fide lumi-
nal progenitor cell is lacking, a characterization of the
body and cap cell populations of TEBs will be necessary
for future studies on GATA-3-mediated luminal cell spec-
ification.
GATA-3 and the Cell Cycle
We observed that the acute loss of GATA-3 in adult mam-
mary glands led to widespread cellular proliferation. This
suggests that GATA-3may play a direct role inmaintainingCethe quiescent state of differentiated luminal cells. Other
studies have reported the connection between GATA
factors andcell-cycle control. In one study, the inactivation
of GATA-3 caused an uncontrolled cellular proliferation in
the nephric duct of the embryonic kidney (Grote et al.,
2006). In another study, GATA-2 inactivation enhanced
the proliferative capacity of embryonic neuroepithelial
cells, whereas the overexpression of GATA-2 was suffi-
cient to inhibit the proliferation of neural progenitors (El
Wakil et al., 2006). Interestingly, in the mammary gland,
we observed a gradient of GATA-3 expression such that
highly proliferative cells (i.e., the body cells of TEBs) ex-
pressed low levels of GATA-3, whereas the nonproliferat-
ing (differentiated) population expressed high levels of
GATA-3. Further work will be necessary to determine
whether the establishment of GATA-3 expression plays
a causal role in cell-cycle control.
Thoughacute loss ofGATA-3 led to cellular proliferation,
the long-term consequence ofGATA-3 loss was caspase-
mediated cell death. This finding contrasts with the results
of other loss-of-function studies involving GATA factors.
The loss of GATA-1 in mature erythroid cells and GATA-3
in committed Th2 cells led to transdifferentiation into alter-
nate cell types (Gallowayet al., 2005;Pai et al., 2004). In our
study, the loss of GATA-3 in committed luminal cells did
not lead to a transdifferentiation into myoepithelial cells;
instead, these cells retained partial luminal character and
exhibited cell death. In the mammary gland, differentiated
luminal cells rely on survival signals from the basement
membrane (Wiseman and Werb, 2002). Detachment of
luminal cells causes a loss of these survival signals, result-
ing in caspase-mediated cell death (Frisch and Screaton,
2001). Thus, the cell death that we observed after long-
term loss of GATA-3 is likely to be a secondary event
following basement-membrane detachment and is not a
primary consequence of GATA-3 loss.
Implications for Breast Cancer
Breast cancers are luminal epithelial cell neoplasias that
can be subdivided into ER+ and ER tumors. ER+ breast
tumors tend to be morphologically well differentiated and
exhibit a relatively good prognosis, whereas the ER
tumors are poorly differentiated and exhibit a relatively
poor prognosis. To date, a series of eleven independent
microarray profiling studies (1009 patients in total) has
analyzed the gene expression signatures of ER+ andFigure 5. Acute Loss of GATA-3 in Adult Mammary Glands Leads to the Expansion of an Undifferentiated Luminal Population
(A–D) Immunofluorescence of mammary glands from 12-week-old WAP-rtTA-Cre; GATA-3flox/+ and WAP-rtTA-Cre; GATA-3flox/floxmice treated with
doxycycline for 5 days. Antibodies used are as follows: (A) keratin 14 (K14, red) and keratin 18 (K18, green), (B) b-casein (green), (C) GATA-3 (red) and
E-cadherin (E-cad, green), and (D) estrogen receptor (ER, red) and GFP (green). Sections were counterstained with DAPI (blue). Cre, WAP-rtTA-Cre;
fl/fl, GATA-3flox/flox; and fl/+, GATA-3flox/+ in (A)–(G).
(E) Microarray profiling of whole mammary glands from 12-week-old WAP-rtTA-Cre; GATA-3flox/+ and WAP-rtTA-Cre; GATA-3flox/flox mice (n = 2)
treated with doxycycline for 5 days. Data are represented as M = log2(Het /Null) where Het = fluorescence intensity of WAP-rtTA-Cre;
GATA-3flox/+ sample and Null = fluorescence intensity of WAP-rtTA-Cre; GATA-3flox/flox sample.
(F) PCNA immunostaining of 5 day doxycycline-treated WAP-rtTA-Cre; GATA-3flox/+ (n = 4) and WAP-rtTA-Cre; GATA-3flox/flox (n = 5) mammary glands.
Scale bars correspond to 25 mm in (A)–(D) and (F).
(G) BrdU analysis of 5 daydoxycycline-treatedWAP-rtTA-Cre;GATA-3flox/+andWAP-rtTA-Cre;GATA-3flox/floxmammary glands.Data are represented as
the number of BrdU-positive cells per mammary duct; n = 50 ducts per condition, and error bars indicate mean ± SEM. ***p < 0.001 (Student’s t test).ll 127, 1041–1055, December 1, 2006 ª2006 Elsevier Inc. 1051
Figure 6. Chronic Loss of GATA-3 in the Adult Mammary Glands Leads to Cell Death and Lactational Insufficiency
(A–C) Immunofluorescence of mammary glands from 12-week-old WAP-rtTA-Cre; GATA-3flox/flox mice treated with doxycycline for 14 days. Control
mammary glands are similar to those shown in Figure 5. Antibodies used are as follows: (A) keratin 14 (K14, red) and keratin 18 (K18, green), (B) GATA-3
(red) and E-cadherin (E-cad, green), and (C) estrogen receptor (ER, red) and GFP (green). Sections were counterstained with DAPI (blue).1052 Cell 127, 1041–1055, December 1, 2006 ª2006 Elsevier Inc.
ER human breast tumors (Bertucci et al., 2000; Farmer
et al., 2005; Gruvberger et al., 2001; Hoch et al., 1999;
Mehra et al., 2005; Perou et al., 2000; Sorlie et al., 2003;
Sotiriou et al., 2003; van ‘t Veer et al., 2002; Wang et al.,
2005; West et al., 2001). In all studies, GATA-3 emerged
as a strong and independent prognostic indicator of
breast cancer. Low GATA-3 expression was strongly as-
sociated with higher histologic grade, positive lymph no-
des, larger tumor size, ER and PR-negative status, and
HER2 overexpression. Meta-analysis of the microarray
data revealed that the prognostic utility of GATA-3 ex-
ceeded that of conventional variables such as ER status
(Mehra et al., 2005). In one study, GATA-3 was identified
as the second-best predictor of breast cancer survival
among 8024 genes (Jenssen et al., 2002). These studies
have established GATA-3 status as being an important
prognostic factor in breast cancer, one that clearly war-
rants further investigation.
Given the fundamental role of GATA-3 inmaintaining the
differentiation of the luminal epithelial cell, we hypothesize
that GATA-3 is causally involved in the pathogenesis of
breast cancer. Well-differentiated tumors with high
GATA-3 expression have a low propensity for metastasis,
whereas poorly differentiated tumors with lowGATA-3 ex-
pression have a greater propensity for metastasis. We
postulate that loss of GATA-3 may play a causal role in
loss of tumor differentiation and malignant conversion in
breast cancer. The loss of GATA-3 in the mammary gland
causes luminal cell proliferation and basement-membrane
detachment. The loss of GATA-3 in breast cancer may
similarly lead to cellular proliferation and basement-mem-
brane detachment, which may result in the acquisition of
metastatic capability. Our future work is directed at deter-
mining what role GATA-3 plays in breast cancer progres-




The floxedGATA-3mouse in the C57Bl/6 strain was kindly provided by
I-Cheng Ho and Sung-Yun Pai (Harvard Medical School). MMTV-Cre
and WAP-rtTA-Cre mice in the C57Bl/6 strain were obtained from
the Mouse Models of Human Cancer Consortium (MMHCC), National
Cancer Institute. b-actin-GFP reporter mice in the FVB/n strain were
from Jackson Laboratory.CeExpression Profiling
TEB microenvironments, mature-duct microenvironments, and distal
stroma regions of mammary glands 2–5 were microdissected from
5-week-old b-actin-GFP reporter mice. RNA was extracted with Trizol
Reagent (Tel-Test), reverse transcribed in the presence of amino-allyl-
dUTP, and coupled to CyScribe dyes (Amersham). Unamplified Cy5-
labeled TEB or mature duct cDNAs and Cy3-labeled stromal cDNAs
were hybridized onto 70-mer oligonucleotide microarrays with
19,500 features (Operon, mouse version 2.0), as described elsewhere
(Barczak et al., 2003). The most highly enriched genes were deter-
mined by calculating M = log2(Cy5/Cy3) for the TEB versus distal
stroma (n = 6) andmature duct versus distal stroma (n = 6)microarrays.
A full analysis of the microarray data can be found elsewhere (Kouros-
Mehr and Werb, 2006).
Breeding and Analysis of Conditional Knockout Mice
All animal experiments were performedwith protocols approved by the
UCSF IACUC. Floxed mice were bred with MMTV-Cre or WAP-rtTA-
Cre mice to obtain Cre; GATA-3flox/+ mice. Cre; GATA-3flox/+ mice
were then bred with GATA-3flox/flox mice to obtain Cre; GATA-3flox/flox,
Cre; GATA-3flox/+, and nontransgenic; GATA-3flox/x mice. Mice were
genotyped as described (Pai et al., 2003). Number 4 (inguinal) mam-
mary glands of MMTV-Cre; GATA-3flox/flox, MMTV-Cre; GATA-3flox/+,
and Non-Tg; GATA-3flox/+ mice were analyzed by carmine whole
mount, asdescribed (Jones et al., 1996). Ductal invasionwasmeasured
from the proximal end of the primary duct to the most distal TEB.
Genomic DNA from the recombined cells of 30-week-old MMTV-Cre;
GATA-3flox/flox, and MMTV-Cre; GATA-3flox/+ mice was purified by
collagenase digestion of mammary tissue, purification of single cells,
and FACS sorting of GFP+ cells (Welm et al., 2002). Genomic DNA
was analyzed with PCR primers specific to the wild-type GATA-3,
floxed GATA-3, and deleted GATA-3 loci, as described (Pai et al.,
2003). For the WAP-rtTA-Cre experiments, 12-week-old mice were
placed on a 3, 5, or 14 day course of doxycycline feed (Bio-Serv). A
subset of mice that were on a 14 day course of doxycycline wasmated
with wild-type males and maintained on doxycycline until day 10 of
lactation, at which time the mice were sacrificed.
Immunofluorescence
Mammary glands were fixed overnight in 4% paraformaldehye and
then paraffin embedded. Sections (5 mm) were rehydrated, processed
with microwave antigen retrieval, and blocked with theM.O.M kit (Vec-
tor Biolabs). Primary antibodies were diluted in M.O.M. diluent and in-
cubated on sections overnight at 4C. Primary antibodies used were
anti-GATA-3 (1:25, HG-31, Santa Cruz Biotechnologies), anti-Estrogen
Receptor (1:30, clone 1D5, DAKO), anti-E-cadherin (1:500, 610181,
Becton-Dickinson), Cy3-anti-a-smooth muscle actin (1:200, 1A4,
Sigma), anti-b-casein (1:100, gift of M.J. Bissell laboratory), anti-Cyto-
keratin 14 (1:500, PRB-155P, Covance), anti-cytokeratin 18 (1:50, Ks
18.04, Progen), anti-PCNA (1:500, PC10, DAKO), anti-caspase-
cleaved cytokeratin 18 (1:100, M30, Roche) and anti-GFP (1:1000,
ab290, Abcam). Sections were then incubated with Alexa 488 and
Alexa 564 secondary antibodies (1:300, Molecular Bioprobes) for(D) Caspase-cleaved keratin 18 immunostaining of 5 day and 14 day doxycycline-treated WAP-rtTA-Cre; GATA-3flox/flox and WAP-rtTA-Cre;
GATA-3flox/+ mammary glands (age = 12 weeks). Cre, WAP-rtTA-Cre; fl/fl, GATA-3flox/flox; and fl/+, GATA-3flox/+ in (D)–(H). Fourteen day dox-treated
control mammary glands were similar to 5 day treated controls in (D) and (E).
(E) Quantification of caspase-cleaved keratin 18 (M30) expression from (D). Data are represented as the percentage of mammary ducts that
contained at least one M30-positive cell; n = 10 ducts per condition.
(F) Carmine-stained whole mounts and GFP whole mounts of number 4 mammary glands from lactating WAP-rtTA-Cre; GATA-3flox/flox (n = 2) and
WAP-rtTA-Cre; GATA-3flox/+ (n = 2) mice treated with doxycycline for 5 weeks. Tissues were harvested at day 10 of lactation. Corresponding H&E-
stained sections are shown in (G).
(H) Weight of pups (in grams) born to 5 week doxycycline-treated WAP-rtTA-Cre; GATA-3flox/flox and WAP-rtTA-Cre; GATA-3flox/+ mothers at day 10
of lactation. Data are represented as mean ± SEM. *p < 0.01 (Student’s t test).
(I) PCR analysis of the FOXA1 promoter in adult mammary gland DNA immunoprecipitated with a GATA-3 antibody, control mouse immunoglobulin,
or no primary antibody control. The PCR product was a 200 bp fragment 0.8 kb upstream of the FOXA1 promoter that contained a GATA binding site.ll 127, 1041–1055, December 1, 2006 ª2006 Elsevier Inc. 1053
1 hr. For BrdU analysis, mice received a 300 ml intraperitoneal injection
of 5 mg/ml BrdU and were sacrificed 3 hr later. Sections were then im-
munostained with FITC-anti-BrdU (1:10, 447583, Becton-Dickinson).
Analysis and three-dimensional rendering were performed by using
the Volocity software package.
ChIP
Primary cultures of adult mammary gland were used in the analysis, as
described (Welm et al., 2005). Adult mammary gland DNA was immu-
noprecipitatedwith theGATA-3 antibody, control mouse immunoglob-
ulin (Jackson ImmunoResearch), or no primary antibody control, as
described (ChIP assay kit, Upstate Biotechnology). PCR amplification
of a 200 bp fragment 0.8 kb upstream of the FOXA1 first exon (primers
50-TACGAGGGCAAGCCACTAAC-30 and 50-ATCTGCCACGCTAAAT
GAGG-30) was performed with the following cycle parameters: 95C
for 5 min, 35 cycles of 94C for 30 s, 55C for 30 s and 72C for
30 s, and a 10 min 72C final extension (HotStarTaq, Qiagen).
Supplemental Data
Supplemental Data include Supplemental References and one figure
and can be found with this article online at http://www.cell.com/cgi/
content/full/127/5/1041/DC1/.
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